Navigation Links
Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Date:9/18/2007

LONDON, Sept. 18 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that it has appointed Rosemary Mazanet M.D., Ph.D. as its interim Chief Executive Officer. Dr. Mazanet has significant experience in both executive and operational management in the biopharmaceutical industry.

Dr. Mazanet serves on the Board of numerous private and public pharmaceutical companies. From June 1998 to February 2004, Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners, L.P., a healthcare investment firm. As Senior Director of Clinical Research at Amgen in the early and mid 1990s, she was responsible for the submission of corporate INDs, the registration strategy and conduct of Phase I, II and III clinical trials. Dr. Mazanet also serves as an independent director at GTx, Inc. (Nasdaq: GTXI) and is a trustee at the University of Pennsylvania, School of Medicine where she received her M.D. and Ph.D. Dr. Mazanet was trained as an oncologist in the Harvard Medical System where she was also a faculty member.

Dr. Mazanet commented, "I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation," said Dr. Mazanet. "We believe this new family of Multifunctional Anti-Inflammatory Drugs (MFAIDS) could bring significant benefits to patients with many different inflammatory conditions including skin, respiratory and gastrointestinal indications."

"Dr. Mazanet has a strong track record in operations, finance and regulatory affairs. We are very fortunate to have attracted the c
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
(Date:5/21/2013)... new study led by George Washington University Professor ... of ice in small droplets is strongly size-dependent, ... the nanoscale. The formation of ice at the ... whose answer also has important implications for climate ... of ice from supercooled water is generally initiated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... by Improving ... Information Management, MILFORD, ... announced that it has joined the BioIT Alliance, an,initiative spearheaded ... and software companies,working together to realize the potential of personalized ...
... StopAfib.org, at, http://www.StopAfib.org, announces that September is Atrial ... called afib or AF., Once considered benign, this ... or stroke. Every five minutes, someone in the,U.S. has ... killer and the #1 cause of,permanent disability, and takes ...
... $15 million development milestone payment to InterMune - ... - Roche to lead ITMN-191 program in Phase 2 -, ... ) today announced that InterMune has earned a $15 million,development ... virus (HCV) NS3 protease inhibitor compound ITMN-191,(referred to as R7227 ...
Cached Biology Technology:Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 2Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 3Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... CORVALLIS, Ore. A 700-mile security wall under construction ... alter the movement and "connectivity" of wildlife, biologists say, ... populations of some species. However, technology and alterations ... animals to move more freely between the two countries, ...
... survival is now better understood. For the first time, ... National Laboratory observed the chemical changes in individual cells ... them. The team tracked the chemical changes in ... can only exist in an oxygen-free environment. They exposed ...
... has discovered a key process in cell growth that can ... assistant professor of biochemistry, found that an overabundance of the ... well as a shortage of the p53 molecule, will lead ... Plk1 molecule indirectly attacks p53 in a process called ubiquitination. ...
Cached Biology News:US-Mexico border wall could threaten wildlife species 2US-Mexico border wall could threaten wildlife species 3US-Mexico border wall could threaten wildlife species 4Scientists track chemical changes in cells as they endure extreme conditions 2Scientists track chemical changes in cells as they endure extreme conditions 3Protein can help cells or cause cancer, Purdue researcher finds 2
Request Info...
...
...
... Inhibits several important steps of angiogenesis including proliferation, ... Also reduces intracellular reactive oxygen species (ROS) level, ... cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: